Follow
Scott Rodig
Scott Rodig
Professor of Pathology, Brigham & Women's Hospital
Verified email at bwh.harvard.edu
Title
Cited by
Cited by
Year
PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma
SM Ansell, AM Lesokhin, I Borrello, A Halwani, EC Scott, M Gutierrez, ...
New England Journal of Medicine 372 (4), 311-319, 2015
39412015
An immunogenic personal neoantigen vaccine for patients with melanoma
PA Ott, Z Hu, DB Keskin, SA Shukla, J Sun, DJ Bozym, W Zhang, A Luoma, ...
Nature 547 (7662), 217-221, 2017
25932017
Clinical features and outcome of patients with non–small-cell lung cancer who harbor EML4-ALK
AT Shaw, BY Yeap, M Mino-Kenudson, SR Digumarthy, DB Costa, ...
Journal of clinical oncology 27 (26), 4247, 2009
24212009
Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK–STAT signaling pathway
MA Meraz, JM White, KCF Sheehan, EA Bach, SJ Rodig, AS Dighe, ...
Cell 84 (3), 431-442, 1996
20701996
Comprehensive analyses of tumor immunity: implications for cancer immunotherapy
B Li, E Severson, JC Pignon, H Zhao, T Li, J Novak, P Jiang, H Shen, ...
Genome biology 17, 1-16, 2016
19322016
Adaptive immunity maintains occult cancer in an equilibrium state
CM Koebel, W Vermi, JB Swann, N Zerafa, SJ Rodig, LJ Old, MJ Smyth, ...
Nature 450 (7171), 903-907, 2007
17742007
Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes
B Chapuy, C Stewart, AJ Dunford, J Kim, A Kamburov, RA Redd, ...
Nature medicine 24 (5), 679-690, 2018
15842018
MYD88 L265P somatic mutation in Waldenström's macroglobulinemia
SP Treon, L Xu, G Yang, Y Zhou, X Liu, Y Cao, P Sheehy, RJ Manning, ...
New England Journal of Medicine 367 (9), 826-833, 2012
14692012
Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
S Koyama, EA Akbay, YY Li, GS Herter-Sprie, KA Buczkowski, ...
Nature communications 7 (1), 10501, 2016
14422016
Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade
BC Miller, DR Sen, R Al Abosy, K Bi, YV Virkud, MW LaFleur, KB Yates, ...
Nature immunology 20 (3), 326-336, 2019
14232019
Integrative analysis reveals selective 9p24. 1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and …
MR Green, S Monti, SJ Rodig, P Juszczynski, T Currie, E O'Donnell, ...
Blood, The Journal of the American Society of Hematology 116 (17), 3268-3277, 2010
14012010
Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors
EA Akbay, S Koyama, J Carretero, A Altabef, JH Tchaicha, ...
Cancer discovery 3 (12), 1355-1363, 2013
13052013
Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial
DB Keskin, AJ Anandappa, J Sun, I Tirosh, ND Mathewson, S Li, ...
Nature 565 (7738), 234-239, 2019
11362019
Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses
SJ Rodig, MA Meraz, JM White, PA Lampe, JK Riley, CD Arthur, KL King, ...
Cell 93 (3), 373-383, 1998
11271998
Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study
AM Lesokhin, SM Ansell, P Armand, EC Scott, A Halwani, M Gutierrez, ...
Journal of clinical oncology 34 (23), 2698-2704, 2016
10552016
Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial
A Younes, A Santoro, M Shipp, PL Zinzani, JM Timmerman, S Ansell, ...
The lancet oncology 17 (9), 1283-1294, 2016
10002016
Ibrutinib in previously treated Waldenström’s macroglobulinemia
SP Treon, CK Tripsas, K Meid, D Warren, G Varma, R Green, ...
New England Journal of Medicine 372 (15), 1430-1440, 2015
9902015
PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies
BJ Chen, B Chapuy, J Ouyang, HH Sun, MGM Roemer, ML Xu, H Yu, ...
Clinical cancer research 19 (13), 3462-3473, 2013
9532013
Crizotinib in ALK-Rearranged Inflammatory Myofibroblastic Tumor
JE Butrynski, DR D'Adamo, JL Hornick, P Dal Cin, CR Antonescu, ...
New England Journal of Medicine 363 (18), 1727-1733, 2010
9432010
Tet1 and Tet2 regulate 5-hydroxymethylcytosine production and cell lineage specification in mouse embryonic stem cells
KP Koh, A Yabuuchi, S Rao, Y Huang, K Cunniff, J Nardone, A Laiho, ...
Cell stem cell 8 (2), 200-213, 2011
8642011
The system can't perform the operation now. Try again later.
Articles 1–20